Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 4, 2004 - Issue 6
Submit an article Journal homepage
18
Views
1
CrossRef citations to date
0
Altmetric
Review

Treatment of recurrent or metastatic renal cell carcinoma

Riyaz NH Shah The Royal Marsden Hospital, Department of Medical Oncology, Sutton SM2 5PT, UK. [email protected]
,
Tanya Ahmad The Institute of Cancer Research, MRCP Cancer Research UK, McElwain Clinical Research Fellow, Section of Medicine, London SW7 3RP, UK. [email protected]
&
Tim G Eisen The Institute of Cancer Research, London SW7 3RP, UK. [email protected]
Pages 1069-1080 | Published online: 10 Jan 2014

References

  • Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancerj Clin. 49, 33–64 (1999).
  • Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer' Clin. 49, 8–31 (1999).
  • Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. Patha 183,131–133 (1997).
  • Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre Le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer80, 987–989 (1997).
  • Ljungberg B, Alamdari Fl, Stenling R, Roos G. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur. Urol. 36, 565–569 (1999).
  • Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am." Surg. Pathol. 25, 275–284 (2001).
  • Zambrano NR, Lubensky IA, Merino MJ, Linehan WM, Walther MM. Histopathology and molecular genetics of renal tumors toward unification of a classification system." Urol. 162, 1246–1258 (1999).
  • deKernion JB, Berry D. The diagnosis and treatment of renal cell carcinoma. Cancer 45,1947–1956 (1980).
  • Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy.j Clin. Oncol. 12,206–212 (1994).
  • Abu-Zidan FM, Sabha M, Salama AL, Nilsson T, Shuhaiber H. Three staged approach to the surgical management of renal cell carcinoma extending into the right atrium. Case report." Cardiovasc. Surg. (Torino)31,595–598 (1990).
  • Glazer AA, Novick AC. Long-Term follow-up after surgical treatment for renal cell carcinoma extending into the right atrium. 1 Urol. 155,448-450 (1996).
  • Samellas W Marks AR. Apparent spontaneous regression of pulmonary metastases following nephrectomy for adenocarcinoma of the kidney." Urol. 85, 494–496 (1961).
  • Samellas W Adenocarcinoma of the kidney: a 10-year apparent cure following the resection of solitary pulmonary metastasis.j Urol. 90,250–252 (1963).
  • Schapira HE, Oppenheimer CD. Spontaneous disappearance of pulmonary metastases in hypernephroma. Final report of 20 year follow-up after nephrectomy." Mt. Sinai Hosp. NY34,11–16 (1967).
  • Markewitz M, Taylor DA, Veenema RJ. Spontaneous regression of pulmonary metastases following palliative nephrectomy. Case report. Cancer 20, 1147–1154 (1967).
  • Mathias DB. A case of spontaneous regression of pulmonary metastases arising from hypernephroma following nephrectomy. Br." Urol. 43,65-68 (1971).
  • Middleton AW Jr. Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol. Clin. North Am. 7, 711–717 (1980).
  • Snow RM, Schellhammer PE Spontaneous regression of metastatic renal cell carcinoma. Urology20,177–181 (1982).
  • Montle JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma.j Urol. 117,272–275 (1977).
  • Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur. Urol. 45, 692–705 (2004).
  • Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon-a2b compared with interferon-a2b alone for metastatic renal-cell cancer. N. Engl. Med. 345,1655-1659 (2001).
  • •• Nephrectomy improves survival in patients receiving systemic immunotherapy.
  • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-a-based immunotherapy compared with interferon-a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
  • •• Nephrectomy improves survival in patients receiving systemic immunotherapy.
  • Middleton RC. Surgery for metastatic renal cell carcinoma.' Urol. 97,973–977 (1967).
  • van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Ear. Urol. 35,197–203 (1999).
  • Swanson DA. Surgery for metastases of renal cell carcinoma. Scand. j Surg. 93, 150–155 (2004).
  • Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Cilia. Oncol. 16,2261–2266 (1998).
  • Wen PY, Loeffler JS. Management of brain metastases. Oncology aluntingt) 13, 941–961 (1999).
  • Halperin EC, Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51, 614–617 (1983).
  • Tong D, Glllick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 50,893–899 (1982).
  • Maor MH, Frias AE, Oswald MJ. Palliative radiotherapy for brain metastases in renal carcinoma. Cancer 62,1912–1917 (1988).
  • Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. j Neurosurg. 98, 342–349 (2003).
  • Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and a-interferon as treatment for metastatic renal carcinoma. Br. J Urol. 63,128–131 (1989).
  • ••A significant number of patients haveprolonged periods of disease stability with no therapy.
  • Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Sernin. Oncol. 22, 42–60 (1995).
  • Kish JA, Wolf M, Crawford ED et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74,916–919 (1994).
  • De Mulder PH, Weissbach L, Jakse G, Osieka R, Blatter J. Gemcitabine: a Phase II study in patients with advanced renal cancer. Cancer Chernother. Pharrnacol. 37, 491–495 (1996).
  • Mertens WC, Eisenhauer EA, Moore M et al. Gemcitabine in advanced renal cell carcinoma. A Phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 4,331–332 (1993).
  • Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin. Oncol. 18, 2419–2426 (2000).
  • Stadler WM, Huo D, George C et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. Urol. 170,1141–1145 (2003).
  • Stadler WM, Halabi S, Ernstoff MS et al. A Phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (MRCC): a report of Cancer and Leukemia Group B #90008. Proc. Am. Soc. Clin. Oncol. 22,14 (2004) (Abstract 4515).
  • Waters JS, Moss C, Pyle L et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br. J Cancer (2004) (In Press).
  • Porta C, Zimatore M, Imarisio I et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. Cancer 100, 2132–2138 (2004).
  • Bloom HJ, Dukes CE, Mitchley BC. Hormone-dependent tumours of the kidney. I. The oestrogen-induced renal tumour of the Syrian hamster. Hormone treatment and possible relationship to carcinoma of the kidney in man. Br. J Cancer 17,611–645 (1963).
  • Karr JP, Pontes JE, Schneider S, Sandberg AA, Murphy GE Clinical aspects of steroid hormone receptors in human renal cell carcinoma. J Surg. Oncol. 23, 117–124 (1983).
  • Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Megestrol acetate: clinical experience. Cancer Treat. Rev. 16,49–63 (1989).
  • Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Cancer Res. 10,6397S-6403S (2004).
  • Coleman RE. Bisphosphonates: clinical experience. Oncologist 9\(Suppl. 4), 14–27 (2004).
  • Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl. J Med. 313,1485-1492 (1985).
  • Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl. J Med. 316,889-897 (1987).
  • Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancerj Sci. Am. 3\(Suppl. 1), S70—S72 (1997).
  • Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin. Oncol. 21, 3127–3132 (2003).
  • Sleijfer DT, Janssen RA, Buter J, de Vries EG, Wlllemse PH, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an out-patient basis.j Clin. Oncol. 10,1119-1123 (1992).
  • Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon-a2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin. Oncol. 11, 1368–1375 (1993).
  • Steineck G, Strander H, Carbin BE et al. Recombinant leukocyte interferon-a2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol. 29,155-162 (1990).
  • Kriegmair M, Oberneder R, Hofstetter A. Interferon-a and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology45,758–762 (1995).
  • Medical Research Council Renal Cancer Collaborators. Interferon-a and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353,14–17 (1999).
  • ••Only randomized Phase III trial to showimproved overall survival for immunotherapy.
  • Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon-a2a, or both in metastatic renal-cell carcinoma. Groupe Francais D'Immunotherapie. N Engl. Med. 338,1272-1278 (1998).
  • Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-a and 5-fluorouracil for metastatic renal cell cancer. Eur. J Cancer 29A (Suppl. 5), S6—S8 (1993).
  • Atzpodien J, Kirchner H, huger HJ et al. IL-2 in combination with IFN-a and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J Cancer 85, 1130–1136 (2001).
  • Allen MJ, Vaughan M, Webb A et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and a-interferon in patients with metastatic renal cell cancer: a Phase II study. Br. J. Cancer83, 980–985 (2000).
  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Oncol. 17, 2530–2540 (1999).
  • •• Defined prognostic factors for survival in metastatic renal cell cancer (RCC).
  • Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. JOncol. 22,454–463(2004).
  • •Defined prognostic criteria in relapsed RCC which may be useful in designing second-line studies.
  • Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med. 5,1359–1364 (1999).
  • Presta LG, Chen H, O'Connor SJ eta]. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
  • Mordenti J, Thomsen K, Licko V, Chen H, Meng YG. Ferrara N. Efficacy and concentration-response of murine antiVEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol. Pathol. 27,14–21 (1999).
  • Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the Von Hippel-Lindau protein. Proc. Natl Acad. Sc]. USA 93,10595–10599 (1996).
  • Takahashi A, Sasaki H, Kim SJ eta]. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 54,4233–4237 (1994).
  • Yang JC, Haworth L, Sherry RM eta]. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl. Med. 349,427–434 (2003).
  • •• An antivascular endothelial growth factor antibody can improve time to progression in metastatic RCC.
  • Rini BI, Halabi S, Taylor J, Small EJ, Schllsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-a or interferon-a plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 10, 2584–2586 (2004).
  • Hainsworth JD, Sosman JA, Spigel DR, Schwert RC. Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma. Proc. Am. Soc. Clin. Oncol. 22,14 (2004) (Abstract 4502).
  • D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Nat] Acad. Sc]. USA 91, 4082–4085 (1994).
  • Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-a by enhancing mRNA degradation. 'Exp. Med. 177, 1675–1680 (1993).
  • Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Irnmunopharrnacology 31,213–221 (1996).
  • Ching LM, Xu Z, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and antitumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br.Cancer 72,339–343 (1995).
  • Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J Cancer 82, 812–817 (2000).
  • Stebbing J, Benson C, Eisen T et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J Cancer 85,953–958 (2001).
  • Srinivas S, Guardino AF. Randomized trial of high and low dose thalidomide in metastatic renal cell carcinoma. Proc. Am. Soc. Cilia. Oncol. 21(2002) (Abstract 2403).
  • Li Z, Amato R, Papandreou C et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (mRcq progressing after interleukin-2 (IL-2) -based therapy (Rx). Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 717).
  • Motzer RJ, Berg W, Ginsberg M eta]. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Oncol. 20,302–306 (2002).
  • Ridenhour KP, Kubinski D, Stindt D, Hall MC, Patton SE, Torti FM. Phase II trial of thalidomide and interferon-a in advanced renal cell carcinoma. Proc. Am. Soc. Cilia. Oncol. 21 (2002) (Abstract 2429).
  • Nathan PD, Walker D, Bridle H et al. A Phase II study investigating the use of thalidomide in conjunction with interferon-a in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 1058).
  • Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon-a2a treatment in metastatic renal cell carcinoma. J Clin. Oncol. 20,1429-1430 (2002).
  • Gordon MS, Manola J, Fairclough D et al. Low-dose interferon-a2b (MN) + thalidomide (T) in patients (Pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A Phase III study of the Eastern Co-operative Oncology Group (E2898). Proc. Am. Soc. Cilia. Oncol. 22 (2004) (Abstract 4516).
  • Amato RJ, Breheny S, Tracy E. Phase I/II Study of thalidomide + interleukin 2 (IL-2) for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 759).
  • Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95,1629–1636 (2002).
  • Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol. 43, 109–114 (1999).
  • Chiloeches A, Marais R. Mitogen activated protein kinase cascades as therapeutic targets in cancer. In: Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins. La Thangue NB, Bandara LR (Eds), Humana Press, NJ, USA (2002).
  • Tsuchiya N, Sato K, Akao T et al. Quantitative analysis of gene expressions of vascular endothelial growth factor-related factors and their receptors in renal cell carcinoma. Tohokuf Exp. Med. 195, 101–113 (2001).
  • Thomas AL, Morgan B, preys J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Sernin. Oncol. 30,32-38 (2003).
  • Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of platelet-derived growth factor-a receptor is associated with tumor progression in clear cell renal cell carcinoma. Am. J Clin. PathoL 120,107–112 (2003).
  • Stumm G, Eberwein S, Rostock-Wolf S et al. Concomitant overexpression of the EGFR and ErbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J Cancer69, 17–22 (1996).
  • Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler U. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res. 63, 2940–2947 (2003).
  • Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Ce1193, 53–62 (2001).
  • Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol. Chem. 272, 4378–4383 (1997).
  • Khosrayi-Far R, Der CJ. The Ras signal transduction pathway. Cancer Metastasis Rev. 13,67–89 (1994).
  • Oka H, Chatani Y, Hoshino R et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55, 4182–4187 (1995).
  • Chan S. Targeting the mammalian target of rapamycin (MTOR): a new approach to treating cancer. Br. J Cancer 91, 1420–1424 (2004).
  • Mills GB, Kohn E, Lu Y et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Sernin. OncoL 30,93–104 (2003).
  • Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN. TOR controls translation initiation and early G1 progression in yeast. MoL Biol. Cell 7, 25–42 (1996).
  • Wilhelm S, Chien DS. BAY 43–9006: preclinical data. Carr. Pharrn. Des. 8, 2255–2257 (2002).
  • Strumberg D, Schuehly U, Moeller JG et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of the Raf kinase inhibitor BAY 43–9006 in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. amyl (2001) (Abstract 330).
  • Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. JOncoL 20,4478–4484(2002).
  • •Trial design specifically structured to examine the cytostatic agents where conventional measures of response are problematic.
  • Ratain MJ, Flaherty KT, Stadler WM et al. Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a Phase II randomized discontinuation trial (RDT). Proc. Am. Soc. Clin. OncoL 22,14 (2004) (Abstract 4501).
  • Flaherty KT, Lee RJ, Humphries R, O'Dwyer PJ, Schiller J. Phase I trial of BAY 43–9006 in combination with carboplatin (C) and paclitaxel (P). Proc. Am. Soc. Clin. OncoL 22 (2003) (Abstract 2854).
  • Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor 5U5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9,1648-1655 (2003).
  • Motzer RJ, Rini BI, Michaelson MD et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a Phase II trial. Proc. Am. Soc. Clin. OncoL 22 (2004) (Abstract 4500).
  • ••Novel kinase inhibitor shows evidence ofactivity in metastatic RCC.
  • Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest. New Drugs21,341–345 (2003).
  • Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin. Cancer Res. 10, 794–801 (2004).
  • Atkins MB, Hidalgo M, Stadler W et al. A randomized double-blind Phase II study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 36).
  • Smith JVV, Ko YJ, Dutcher J et al. Update of a Phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oricol. 22, 14S (2004) (Abstract 4513).
  • Volk J, Sel S, Ganser A, Schoffski P Tumor cell-based vaccination in renal cell carcinoma: rationale. Approaches, and recent clinical development. Carr. Drug Targets 3,401–408 (2002).
  • Ayigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 13,51–64 (1999).
  • Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer IrnmunoL Irmnunother. 51,637–644 (2002).
  • Hold. L, Zelle-Rieser C, Gander H eta]. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8,3369–3376 (2002).
  • Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. 10,6347S-6352S (2004).

Websites

  • Tuma RS. CFS: Thalidomide Shows Promise in Treatment of Renal Cell Carcinoma www.docguide.com/news/content.nsf/news/ 8525697700573E1885256C72007A98C3 ?Open&id = 48DDE4A70E09A9698525 68880078C249&count = 10 (Accessed November 2004)
  • Promising New Treatment For Aggressive Kidney Cancer. www.mskcc.org/mskcc/htm1/48474.cfm (Accessed November 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.